Two pharmaceutical giants want to "marry"? Global revenue in the top 20 in 2019

FiercePharma,PharmaceuticalS.com
, previously released its list of the top 20 pharmaceutical companies in the world in 2019, with AstraZeneca and Gilead both on the list, with total revenues of $24.384 billion and $22.449 billion, respectivelyThe merger, based on 2019 revenues, would create a new company with annual revenueof $46.8 billion and is expected to rank among the top five global pharmaceutical companies in revenue, AstraZeneca is now worth $140bn and Gilead has a market capitalisation of more than $96bnIn this calculation, if the two companies merge, the market value will be more than $236 billionrecently, industry insiders said the two giants are in contact for a possible merger involving $96bnHowever, as no decision has yet been made, formal negotiations have not yet begunthis news has undoubtedly caused a high level of discussion in the industryIf the two giants are successful, the deal will surpass BMS's $74bn acquisition of Celgene in early 2019, making it one of the biggest pharmaceutical mergers in history, and the industry as a whole is expected to reshapeauslebank, the UK pharmaceutical giant, has a range of products in the fields of nerves, breathing, digestion, cardiovascular, oncology and anesthesia, according toGilead is a U.S.-based innovative pharmaceutical company with products covering AIDS, hepatitis B, hepatitis C, cardiovascular disease, cystic fibrosis, respiratory diseases and antifungal sydgins, some are not optimistic about the partnership because the two companies don't seem to have much correlation"If it is bullish on Gilead's Redseve, it is not enough to justify this big acquisition, and the deal could weaken AstraZeneca's research and development capabilities in this area.", industry insiders point out that current executives on both sides were former colleaguesPascal Soriot was Roche's CMO until he became AstraZeneca's CEO in 2012, while Daniel Oday was Roche's CEO before joining Gilead but industry insiders believe the two giants' product lines complement each other It is well known that Gilead's strength lies in the field of AIDS medicine In 2019, the company's AIDS-related medical products sold about $16.438 billion, accounting for more than 70 percent of total sales revenue, and oncology has been its short board currently, Gilead hopes to open up the cancer drug market through cell therapy, which has previously been expanded through the acquisition of Kate Pharmaceuticals, which was approved by the FDA in October 2017 to become the second CAR-T product to go on the market worldwide In fiscal 2019, Y Drug achieved sales of $456 million, up 72.7 percent from $264 million in 2018 AstraZeneca has a clear advantage in oncology drugs, but short-terms in the fight against infection The company's 2019 sales of cancer drugs were $8.667 billion Among them, ositinib, prostate cancer of Goshereline, breast cancer fluvesgroup injections and other tumor drugs have contributed more than $100 million in sales revenue Of this total, Ositinib, which is used to treat non-small cell lung cancer, achieved revenue of $3.189 billion, up 71.5 percent year-on-year in response to takeover rumors, AstraZeneca China officials responded to the media that AstraZeneca China would not comment on the current market rumors Gilead has yet to respond.